PharmaSphere: Global Dealmaking and Operations Strategies in the CRO Market...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 13
1.2 List of Figures 13
2 Introduction 15
2.1 Report Scope 15
2.1.1 GlobalData Selection Criteria 16
2.1.2 Companies Covered 16
2.2 Upcoming Reports 17
2.3 Recently Published Reports 17
3 CRO Market Dynamics 18
3.1 Outsourcing Service Delivery Models 18
3.1.1 Fully Integrated Service Model 18
3.1.2 Functional Service Model 19
3.1.3 The Bottom Line: Use a Hybrid Approach 19
3.2 Quintiles Goes Public 20
3.2.1 Quintiles IPO Raises $947M, Pricing an Increased Number of Shares at Top Range 20
3.3 Weak Demand for Preclinical Services Causes CROs to Economize 20
3.4 CROs are Transitioning into Becoming Experts in Biologics Manufacturing 22
3.4.1 WuXi Will Become a Leader in Biologics Manufacturing through its Multi-pronged Strategy 23
3.4.2 Catalent Opens New Manufacturing Center for Biologic Drug Development 25
3.4.3 ShangPharma Inks Two mAb Partnerships 26
3.5 Emerging Locations in Asia Will See the Greatest Investment and Growth 27
3.5.1 Location, Location – Footprint Growth Has Become More Important than Cost Reduction 27
3.5.2 Will Concerns about Patient Safety Bring Down the Indian Clinical Trial Market? 29
3.6 eClinical Technologies Will be Key Drivers to Accelerating Time-to-Market 30
3.6.1 Icon and Cerner Team Up to Streamline Late-Phase Studies 31
3.6.2 Parexel Introduces MyTrials Platform 31
3.6.3 INC Research Expands Partnership with Medidata Solutions 32
3.6.4 Quintiles Unveils its Next-Generation Infosario Analytics Platform 33
3.6.5 Covance Launches Xcellerate to Increase Clinical Trial Optimization 33
4 Collaboration and Acquisition Strategies 34
4.1 Overview 34
4.2 M&A Analysis 38
4.2.1 KKR Makes a Splash into CRO Biz with PRA Buy 38
4.2.2 Quintiles Invests in Personalized Medicine 39
4.2.3 Patheon Completes Purchase of Banner Pharmacaps 39
4.2.4 Clinipace Doubles in Size with Paragon Buyout 40
4.2.5 Accenture Complements its R&D Service Offerings with Acquisition of Octagon 40
4.2.6 Catalent Pharma Buys Aptuit’s CTS Business 41
4.2.7 Charles River and Covance Expand Microbial Identification Capabilities 41
4.3 Strategic Partnerships with Large Pharmaceutical Clients 42
4.3.1 Quintiles and Merck Serono Announce Innovative Clinical Development Partnership 42
4.3.2 Charles River and AstraZeneca Align to Accelerate Drug Development 43
4.3.3 Covance Deals 43
4.3.4 Pfizer Improves Clinical Trial Flexibility with Icon and Parexel Partnership 44
4.3.5 Aptuit and GSK Extend Strategic Alliance 44
4.3.6 INC Research Enters into FSP Collaboration with Astellas 45
4.3.7 PRA Announces Strategic Biosimilar Development Agreement with Amgen 45
4.3.8 Parexel and Catalent Combine Core Competencies to Streamline Supply Chain 46
5 Regional Analysis 47
5.1 Overview 47
5.2 North America Landscape Assessment 50
5.2.1 Pharma’s Large Revenue Base in North America Continues to Drive CRO Sector Growth 50
5.3 Strategic Partnerships 52
5.3.1 Covance Collaborates with M2Gen and BioPontis Alliance 52
5.3.2 AMRI Signs Agreement to License its Novel Tubulin Inhibitor Program to Chai Therapeutics 53
5.3.3 Ockham Completes Acquisition of Nexus Oncology 54
5.3.4 Synteract and HCR Combine to Form Multinational CRO 54
5.3.5 Accelovance Buys Radiant’s CRO Division 55
5.3.6 Theorem Forms Relationship with IVD Consultancy Emergo Group 55
5.4 Operations and Global Service Delivery 57
5.4.1 AMRI Realigns its Drug Discovery Services 57
5.4.2 PPD and Icon Grow Bioassay Capabilities in the US 57
5.5 Revenue and Growth Leaders 59
5.5.1 Revenue 59
5.5.2 Revenue Growth YtY 61
5.6 Europe Landscape Assessment 62
5.6.1 European CRO Market Witnessed a Significant Pullback in Growth 62
5.7 Strategic Partnerships 64
5.7.1 TFS International Acquires Italian CRO Dimensione Ricerca 64
5.7.2 Quintiles Signs Deal to Bring Almirall’s LAMA Therapy to the UK 64
5.7.3 Icon Selected by European Pharma Companies as a Global Strategic Partner 65
5.7.4 CromSource Adds Early Phase Research Unit in Partnership with CRC 65
5.7.5 Covance Inks Tech Transfer Deal with France’s Inserm Transfert SA 66
5.8 Operations and Global Service Delivery 67
5.8.1 Patheon Invests in its SoluPath Program in the UK 67
5.8.2 Celerion Expands Belfast Facility with Containment Room for Biologics Studies 68
5.8.3 Harlan Labs Announces Major Investment in Switzerland 68
5.9 Revenue and Growth Leaders 70
5.9.1 Revenue 70
5.9.2 Revenue Growth YtY 72
5.10 Asia-Pacific Landscape Assessment 73
5.10.1 APAC Market Remains Hot for Clinical Outsourcing 73
5.11 Strategic Partnerships 76
5.11.1 Japanese CROs Grow their Domestic Footprints 76
5.11.2 AMRI Drives SmartSourcing Strategy in Japan 77
5.11.3 Covance-BML Boost Clinical Trial Lab in Japan 77
5.11.4 EPS Corporation Separates Business Units to Streamline Efficiency 78
5.11.5 Frontage Hired by Local Chinese Clients to Develop Drugs Overseas 78
5.11.6 DKSH Expands Services in South East Asia 79
5.12 Operations and Global Service Delivery 80
5.12.1 GVK BIO Selects New Distributor in Taiwan 80
5.12.2 Max Neeman International Grows Regional Footprint 80
5.12.3 ClinTec International 81
5.13 Revenue and Growth Leaders 81
5.13.1 Revenue 81
5.13.2 Revenue Growth YtY 83
5.14 Emerging Markets Landscape Assessment 84
5.14.1 BRICs and Other Emerging Regions Still Represent Huge Untapped Markets for R&D 84
5.15 Strategic Partnerships 86
5.15.1 Central and Latin America 86
5.15.2 Emerging EMEA 87
5.15.3 China 89
5.15.4 India 90
5.15.5 Rest of Asia 91
5.16 Operations and Global Service Delivery 94
5.16.1 Expand Strategic Investment in Emerging Markets to Support Business Growth 95
5.17 Revenue and Growth Leaders 99
5.17.1 Revenue 99
5.17.2 Revenue Growth YtY 100
5.17.3 Global Laboratory Accreditations and Certifications 101
6 Firm Utilization 103
6.1 Excerpt from CRO Benchmark Report: Heat Mapping 104
6.1.1 Covance Was the Firm Utilization Leader in 2012 104
6.2 Firm Utilization Metrics 105
6.2.1 Headcount Growth YtY 105
6.2.2 Revenue per Employee 106
6.2.3 Clinical Services Revenue per Clinical Services Employee 107
6.2.4 G&A Expense per G&A Employee 109
6.2.5 S&M Expense per S&M Employee 110
6.3 Human Capital Leadership Changes 111
6.3.1 Source Therapeutic and Regional Expertise to Boost Clinical Operations 111
6.4 Capital Management: Heat Map 113
6.4.1 EPS Was the Capital Management Leader in 2012 due to its Higher Liquidity 113
6.5 Capital Structure Metrics 114
6.5.1 Debt/Equity Ratio 114
6.5.2 Current Ratio 115
6.5.3 Cash Ratio 116
6.6 Share Offerings and Debt Restructurings 117
6.6.1 Proceeds from Share Repurchases Used to Pay-down Debt and Finance Acquisitions 117
7 Future Outlook 118
7.1 CRO Market 118
7.2 Vendor Positioning 120
8 Appendix 121
8.1 Research Methodology 121
8.1.1 Coverage 121
8.1.2 Secondary Research 121
8.2 About the Author 122
8.2.1 Adam Dion, Industry Analyst 122
8.3 Director, Healthcare Industry Dynamics 123
8.4 Global Head of Healthcare 123
8.5 About the Industry Dynamics Team 123
8.6 About GlobalData 124
8.7 Disclosure Information 124
8.8 Disclaimer 124